

VPA10990/003/001

Unicillin 300 mg/ml Suspension for Injection

Variation	Summary	Date
Vet - F.II.e.5 a)	VRA-R - Vet - F.II.e.5 a) - a) Change in the number of units (e.g. tablets, ampoules, etc.) in a pack outside the range of the currently approved pack sizes - F.II.e.5 a) Quality Changes - Container closure system -Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack outside the range of the currently approved pack sizes	06/02/25
Vet - F.II.b.4 z)	VRA-S - Vet - F.II.b.4 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.b.4 z) Quality Changes - Finished Product -Manufacture - Change in the batch size (including batch size ranges) of the finished product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	27/08/24
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	11/06/24
Vet - C2	VNRA - Vet - C2 - Change(s) in the Summary of Product Characteristics (SPC), labelling or package leaflet intended to implement the outcome of a Union interest referral procedure according to Article 83 of Regulation (EU) 2019/6 - C2 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the Summary of Product Characteristics (SPC), labelling or package leaflet intended to implement the outcome of a Union interest referral procedure according to Article 83 of Regulation (EU) 2019/6	03/05/24
Vet - F.II.f.1 c)	VRA-S - Vet - F.II.f.1 c) - c) Change in storage conditions of the finished product or the diluted/reconstituted product - F.II.f.1 c) Quality Changes -Stability - Change in the shelf-life or storage conditions of the finished product - Change in storage conditions of the finished product or the diluted/reconstituted product	24/10/23
Vet - F.I.f.1	VRA-S - Vet - F.I.f.1 - 1. Substantial changes in the updated	20/04/23

	version of the ASMF or the active substance part of the dossier - F.I.f.1 Quality Changes - Active Substance - Other changes to the active substance - Substantial changes in the updated version of the ASMF or the active substance part of the dossier	
--	--	--